Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)

Hepatocellular Carcinoma Clinical Trial

Official title:

Efficacy and Safety of Drug-eluting Bead TACE VS Conventional TACE for Unresectable Hepatocellular Carcinoma: a Multicenter, Prospective Cohort Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03969576
• Other study ID #: DEB-TACE-HCC
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 15, 2020
• Est. completion date: June 15, 2022

Study information

• Verified date: February 2020
• Source: Fourth Military Medical University
• Contact: Guohong Han, MD PHD
• Phone: +86-2984771528
• Email: hangh[@]fmmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

this multi-center prospective cohort study is to evaluate the efficacy and the safety of drug-eluting bead TACE compared with conventional TACE in terms of objective response in unresectable HCC

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 344
• Est. completion date: June 15, 2022
• Est. primary completion date: June 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Prior informed consent

2. Confirmed Diagnosis of HCC: a. Cirrhotic subjects: Clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria. HCC can be defined in cirrhotic subjects by one imaging technique (CT scan, MRI, or second generation contrast ultrasound) showing a nodule larger than 2 cm with contrast uptake in the arterial phase and washout in venous or late phases or two imaging techniques showing this radiological behavior for nodules of 1-2 cm in diameter. Cytohistological confirmation is required for subjects who do not fulfill these eligibility criteria. b. Non-cirrhotic subjects: For subjects without cirrhosis, histological or cytological confirmation is mandatory. Documentation of original biopsy for diagnosis is acceptable

3. Patients with unresectable Barcelona Clinic Liver Cancer (BCLC) stage A and BCLC B, and all patients have a intermediate or high tumor burden (the diameter of largest tumor plus tumor number is more than 6)

4. Child Pugh class A/B(7) class without decompensated liver cirrhosis.

5. ECOG Performance Status 0 score

6. At least one uni-dimensional lesion measurable by MRI or CT according to the RECIST 1.1 criteria

7. Male or female subject larger than 18 years of age

8. Life expectance of at least 12 weeks.

9. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and 4 weeks after the completion of trial

10. Adequate bone marrow, liver and renal function as assessed by central lab by means of the following laboratory requirements from samples within 7 days prior to randomization:

1. Hemoglobin > 9.0 g/dl

2. Absolute neutrophil count (ANC) >1,500/mm3

3. Platelet count=50x109/L

4. ALB=28g/L

5. Total bilirubin < 2 mg/dL

6. Alanine aminotransferase(ALT) and aspartate aminotransferase(AST) < 5 x upper limit of normal

7. Blood urea nitrogen(BUN) and creatinine < 1.5 x upper limit of normal

8. International normalized ratio(INR) < 1.7, or prothrombin time(PT) < 4 seconds above control

Exclusion Criteria:

1. Portal vein or any vascular invasion

2. Presence of extra hepatic spread

3. Presence of metastasis in biliary tract or obstruction of biliary tract

4. Presence of metastasis in brain or presence of symptom of the brain metastasis but lack of further examination to exclude brain metastasis

5. Poor blood supply for the liver tumor lesions; poor blood supply refers that the tumor lesions fail to show obvious contrast uptake in the arterial phase and washout in venous or late phases by CT scan or MRI

6. Any contraindications for hepatic embolization procedures:

1. Known hepatofugal blood flow

2. Known porto-systemic shunt

3. Renal failure / insufficiency requiring hemo-or peritoneal dialysis

7. History of cardiac disease:

1. Congestive heart failure >New York Heart Association (NYHA) class 2

2. Uncontrolled hypertension

8. Known history of HIV infection

9. Patients who have previously been receiving any treatments against HCC

10. Active clinically serious infections (> grade 2 NCI-CTCAE Version 4.0), except for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection

11. Contraindication of Anthracyclines administration, such as Doxorubicin

12. Concurrent with other cancer

13. Pregnant or breast-feeding subjects

14. Women of childbearing age did not take any contraceptive measures

15. Clinically significant gastrointestinal bleeding within 12 weeks prior to start of study

16. Major surgery within 3 weeks prior to start of study drug (e.g. thoracolaparotomy is not allowed, but noninvasive surgery, e.g. biopsy, is allowed)

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Procedure:
• DEB-TACE
Patients in the DEB-TACE group received a maximum dose of 4 ml of DC bead (diameter 75-500 um) loaded with a maximum dose of 150 mg of anthracyclines drugs, such as doxorubicin. The anticancer agents and the diameter of DC Bead for individual patient will be selected according to the common clinical practice of each center. Treatment endpoint consisted of stasis of flow within feeding vessel(s) or completed delivery of maximum single-session dose of 150 mg doxorubicin. TACE will be repeated "on demand" according to the radiological response.
• cTACE
Patients in the cTACE group were treated with anthracyclines, such as doxorubicin, in a mixture of lipiodol. Administration of the anticancer in oil emulsion was followed by injection of embolic materials such as gelfoam or PVA particles until complete stasis in segmental or subsegmental arterial branches. the tumor-feeding vessels should be superselected whenever possible. The anticancer agents for individual patient will be selected according to the common clinical practice of each center. TACE will be repeated "on demand" according to the radiological response.

Locations

Country	Name	City	State
China	Xijing Hospital of Digestive Diseases, Fourth Military Medical University	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
Fourth Military Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate	the percentage of patients who achieved complete response (CR) and partial response (PR) as the best response, according to the modified Response Evaluation Criteria In Solid Tumours (mRECIST) criteria	Tumor response will be assessed at week 4 and week 12 after initiation of treatment and thereafter every 8 weeks, up to 1 year
Secondary	Overall survival	Overall survival (OS) is measured from the treatment start until all-cause death or the last follow-up date	The last patient has been on study for 1year
Secondary	Time to progression	Time to progression is measured from the treatment start to the radiologically confirmed progression	The last patient has been on study for 1year
Secondary	Adverse event	The terms and grade of adverse event will be present according to the Common Terminology Criteria for Adverse Event (CTCAE version 4.0)	The adverse event will be assessed during in hospital and every 4 weeks, up to 1year
Secondary	Progression-free survival	Progression-free survival (PFS) is measured from the treatment start until all-cause death or untreatable progression (vascular invasion, extra hepatic spread, the Eastern Cooperative Oncology Group (ECOG) performance status >2, and Child-Pugh grade over C, but except hepatic new nodule)	The last patient has been on study for 1year
Secondary	Time to response	Time to response (TTR) is measured from the treatment start to the firstly radiologically confirmed complete response or partial response.	The last patient has been on study for 1year
Secondary	Duration of response	Duration of response (DOR) is measured from the first-time confirmed complete response or partial response to the date of radiological progression	The last patient has been on study for 1year